Company intelligence / Profile preview

Kardium

Burnaby/Vancouver area*, British Columbia, Canadakardium.com ↗

Ownership: Private
Employees: ~260
Development stage: Commercial

Overview

Recent clinical data from the PULSE-EU trial and Heart Rhythm Society annual meeting show the Globe System achieved freedom from atrial arrhythmia at one year of 84.2% in paroxysmal AF patients and 80% in persistent AF patients. The device demonstrated safety, high-definition mapping, rapid single-shot pulmonary vein isolation, and durable results across multiple published studies. The system remains investigational only as of June 2025. Enrollment for pivotal US IDE study ("PULSAR") completed April 2024.

Therapeutic areas: Cardiovascular
Modalities: DeviceCatheter-based ablation system (specifically Pulsed Field Ablation and Radiofrequency Ablation)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Globe PF System

Commercial

Indications: Atrial fibrillation

Beyond the preview

Go deeper on Kardium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kardium.